Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPEB-01: Olaparib maintenance with Pembrolizumab and Bevacizumab in BRCA non-mutated platinum-sensitive recurrent ovarian cancer
KCT0005144Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, pembrolizumab, bevacizumab in ovarian cancer, sponsored by Merck & Co.. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on KCT0005144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005144.